Literature DB >> 6134993

Cancer surveillance in ulcerative colitis. Experience over 15 years.

J E Lennard-Jones, B C Morson, J K Ritchie, C B Williams.   

Abstract

In the years 1966-80, 303 patients with radiologically extensive ulcerative colitis were followed up regularly, both by clinical assessment and by mucosal biopsies, to detect dysplastic (precancerous) change. Moderate or severe dysplasia (but no carcinoma) was found in the specimen in 8 patients treated surgically. Despite regular surveillance, carcinoma developed in 13 of the 186 patients with a history of disease for ten years or more. Of the total sixteen carcinomas in these 13 patients, eleven were Dukes stage A, three stage B, one stage C, and one was inoperable. There has been 1 death from carcinoma in this series over the fifteen year observation period. The method of follow-up has probably prevented the development of carcinoma in 8 patients and permitted diagnosis of carcinoma at a stage when cure is likely in 11. The incidence of moderate or severe dysplasia and carcinoma in these patients with mild or symptomless extensive colitis shows that either proctocolectomy or careful follow-up should be advised once the duration of symptoms reaches ten years.

Entities:  

Mesh:

Year:  1983        PMID: 6134993     DOI: 10.1016/s0140-6736(83)90129-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  59 in total

1.  Ten year follow up of ulcerative colitis patients with and without low grade dysplasia.

Authors:  C H Lim; M F Dixon; A Vail; D Forman; D A F Lynch; A T R Axon
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

2.  Risk of ulcerative colitis-associated colorectal cancer in China: a multi-center retrospective study.

Authors:  Wei Gong; Nonghua Lv; Bangmao Wang; Ye Chen; Yinglong Huang; Wenshen Pan; Bo Jiang
Journal:  Dig Dis Sci       Date:  2011-09-22       Impact factor: 3.199

Review 3.  Screening for colorectal cancer in ulcerative colitis: dubious benefits and high costs.

Authors:  S Gyde
Journal:  Gut       Date:  1990-10       Impact factor: 23.059

4.  Mechanistic insight into the ability of American ginseng to suppress colon cancer associated with colitis.

Authors:  Xiangli Cui; Yu Jin; Deepak Poudyal; Alexander A Chumanevich; Tia Davis; Anthony Windust; Anne Hofseth; Wensong Wu; Joshua Habiger; Edsel Pena; Patricia Wood; Mitzi Nagarkatti; Prakash S Nagarkatti; Lorne Hofseth
Journal:  Carcinogenesis       Date:  2010-08-20       Impact factor: 4.944

Review 5.  Colonoscopic surveillance in ulcerative colitis--dysplasia through the looking glass.

Authors:  J B Fozard; M F Dixon
Journal:  Gut       Date:  1989-03       Impact factor: 23.059

6.  The Aryl Hydrocarbon Receptor is a Repressor of Inflammation-associated Colorectal Tumorigenesis in Mouse.

Authors:  Carol J Díaz-Díaz; Sean M Ronnekleiv-Kelly; Manabu Nukaya; Peter G Geiger; Silvia Balbo; Romel Dator; Bryant W Megna; Patrick R Carney; Christopher A Bradfield; Gregory D Kennedy
Journal:  Ann Surg       Date:  2016-09       Impact factor: 12.969

7.  Nearly a Third of High-Grade Dysplasia and Colorectal Cancer Is Undetected in Patients with Inflammatory Bowel Disease.

Authors:  Swathi Eluri; Alyssa M Parian; Berkeley N Limketkai; Christina Y Ha; Steven R Brant; Sharon Dudley-Brown; Jonathan E Efron; Sandy G Fang; Susan L Gearhart; Michael R Marohn; Stephen J Meltzer; Safar Bashar; Brindusa Truta; Elizabeth A Montgomery; Mark G Lazarev
Journal:  Dig Dis Sci       Date:  2017-06-19       Impact factor: 3.199

8.  Colonoscopy, mucosal biopsy and brush cytology in the assessment of patients with colorectal inflammatory bowel disease.

Authors:  W H Isbister; R K Gupta
Journal:  Surg Endosc       Date:  1989       Impact factor: 4.584

9.  [Preneoplasias of the large intestine].

Authors:  F P Gall
Journal:  Langenbecks Arch Chir       Date:  1985

10.  Histochemical study of colonic cancer in experimental colitis of rats.

Authors:  T Tamaru; H Kobayashi; S Kishimoto; G Kajiyama; F Shimamoto; W R Brown
Journal:  Dig Dis Sci       Date:  1993-03       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.